{"id":241995,"date":"2026-09-10T16:41:24","date_gmt":"2026-09-10T11:11:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=241995"},"modified":"2026-09-10T16:41:24","modified_gmt":"2026-09-10T11:11:24","slug":"formulations-stock-rises-111-percent-in-3-years","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/formulations-stock-rises-111-percent-in-3-years\/","title":{"rendered":"This Formulations Stock Rises 111% in 3 Years: What Doubled Investor Money?"},"content":{"rendered":"

Ipca Laboratories CMP approx Rs 1,970.90 (10 Sep 2026). 3-year return 111.14%, rank 39 of 101. 52W range Rs 1,251.60 to Rs 2,001.50. Market cap Rs 49,820 Cr. PE 36.23.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Ipca Laboratories, a branded medicines and API maker, is the formulations stock that returned approximately 111% in three years. The rally came from a profit recovery after FY23, the Unichem acquisition and steady outperformance in the Indian market. Q1 FY27 profit rose 72% and guidance was upgraded, but the share now trades near its 52-week high.<\/p>\n<\/div>\n

This formulations stock has more than doubled investor money in three years, turning Rs 1 lakh into roughly Rs 2.11 lakh. One Mumbai-based drugmaker delivered a 3-year return of 111.14%, ranking 39th in a screen of 101 large-cap and mid-cap NSE shares, as of 10 September 2026.<\/p>\n

The company is Ipca Laboratories Ltd<\/a> (NSE: IPCALAB), a maker of branded medicines, generics and active pharmaceutical ingredients (APIs) with a strong presence in pain management, cardiology and anti-malarials. The Ipca Laboratories share price closed near Rs 1,970.90 on 10 September 2026, up about 0.4% from the previous close of Rs 1,963.60, giving it a market cap of approximately Rs 49,820 crore. Three years ago, the formulations stock traded at around Rs 933.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n